Table 3:

ILD subtype-stratified associations between validated biomarkers and progressive fibrosing ILD phenotype in the overall cohort (n=589)

	OR (95% CI)			Heterogeneity p value*
	Chronic hypersensitivity pneumonitis (n=242)	Connective tissue disease-associated ILD (n=245)	Unclassifiable ILD (n=102)
AGER	0·59 (0·41–0·84)	0·56 (0·40–0·78)	0·75 (0·45–1·24)	0·63
ANGPTL4	1·55 (1·02–2·38)	1·95 (1·29–2·95)	1·82 (0·92–3·60)	0·75
CXCL17	1·34 (0·95–1·89)	1·71 (1·21–2·40)	1·78 (1·09–2·91)	0·52
DPP10	2·24 (1·40–3·57)	1·47 (0·99–2·19)	1·66 (0·93–2·94)	0·4
FASLG	0·32 (0·26–0·65)	0·84 (0·58–1·22)	0·57 (0·29–1·13)	0·06
FCAR	2·24 (1·49–3·38)	1·62 (1·12–2·33)	1·45 (0·83–2·52)	0·36
HGF	2·58 (1·51–4·40)	2·40 (1·46–3·93)	1·51 (0·80–2·83)	0·40
IL17C	1·37 (1·08–1·73)	1·41 (1·11–1·81)	1·62 (1·06–2·47)	0·79
ITGB6	2·71 (1·76–4·19)	3·16 (1·83–5·46)	3·43 (1·66–7·11)	0·83
KRT19	1·92 (1·48–2·50)	2·02 (1·50–2·71)	2·03 (1·29–3·19)	0·96
MMP10	1·85 (1·36–2·52)	1·52 (1·10–2·08)	1·28 (0·86–1·91)	0·34
PLAUR	2·50 (1·34–4·66)	5·10 (2·73–9·51)	2·11 (0·94–4·74)	0·15
PRSS8	1·20 (0·76–1·88)	3·15 (1·87–5·34)	2·37 (1·05–5·35)	0·02
SCGB3A2	1·54 (1·23–1·92)	1·71 (1·35–2·16)	1·47 (1·07–2·02)	0·72
SPON1	2·89 (1·69–4·94)	2·96 (1·70–5·13)	1·62 (0·84–3·13)	0·32
TGFA	2·34 (1·44–3·80)	1·76 (1·18–2·61)	1·48 (0·90–2·43)	0·42
TNFRSF11B	2·02 (1·19–3·45)	1·53 (0·95–2·56)	4·33 (1·76–10·67)	0·13

ORs are per unit change in log2-transformed biomarker concentration. OR=odds ratio. ILD=interstitial lung disease.

^*Test of whether progressive fibrosing ILD biomarker association varies by ILD subtype.